News articles about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1109128868998 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Agios Pharmaceuticals (NASDAQ AGIO) traded down 2.51% on Friday, reaching $61.46. The company had a trading volume of 477,021 shares. The company’s market capitalization is $2.96 billion. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74. The company’s 50 day moving average price is $55.14 and its 200-day moving average price is $50.99.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.24. The company had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm’s quarterly revenue was down 66.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.64) earnings per share. On average, equities analysts predict that Agios Pharmaceuticals will post ($6.43) earnings per share for the current fiscal year.

A number of brokerages have recently commented on AGIO. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, June 11th. Credit Suisse Group reissued an “outperform” rating and set a $61.00 price target on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Finally, Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $67.25.

TRADEMARK VIOLATION NOTICE: “Agios Pharmaceuticals (NASDAQ:AGIO) Earns Media Sentiment Score of 0.15” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at

In related news, CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares in the company, valued at $179,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Biller sold 23,146 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.60, for a total value of $1,379,501.60. Following the completion of the sale, the insider now owns 8,410 shares of the company’s stock, valued at approximately $501,236. The disclosure for this sale can be found here. Insiders sold 79,120 shares of company stock valued at $4,557,207 in the last quarter. 10.55% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.